OR WAIT null SECS
April 25, 2023
The leaked study summary found that Carvykti (ciltacabtagene autoleucel) reduced disease progression by 74%.
April 24, 2023
The Supreme Court’s action leaves open the prospect of further rulings that could undermine FDA’s approval process.
BioChain has reached partnerships with NanoString and 10x Genomics to extend its spatial multiomics services.
JMI Laboratories and bioMérieux will work to improve microbiology diagnostics tools.
April 21, 2023
A report from Business Standard highlighted India’s recent growth in the pharma sector.
April 20, 2023
GSK has reached an agreement to acquire late-stage biopharmaceutical company BELLUS Health.
SAB Biotherapeutics has received both breakthrough and fast track designations from FDA for its lead antibody drug candidate for treating influenza.
April 18, 2023
Jaeger notes that the program is focused on addressing specific scientific questions that will produce immediate impacts on how CDER and FDA make drug approval decisions.
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.
Moderna and Merck reported that a combination therapy involving pembrolizumab and an mRNA demonstrated a 44% reduction in recurrence or death in cancer patients compared to non-combination treatments.